



## Financial Tear Sheet

### Corporate Profile

Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

### Primary IR Contact

Shawn Bevec  
 Vice President Investor Relations  
**Phone:** 973-520-2900  
[Investor@QuestDiagnostics.com](mailto:Investor@QuestDiagnostics.com)

### Stock Performance

DGX (Common Stock)	
Exchange	NYSE (US Dollar)
Price	\$87.81
Change (%)	▲ 2.31 (2.70%)
Volume	2,099,490
52 Week Low	\$78.95
Market Cap	\$11,948,491,540
Rolling EPS	5.29
PE Ratio	16.5992
Shares Outstanding	136,072,105
Data as of 02/15/19 4:03 p.m. ET	



### Recent Press Releases

02/14/19

Quest Diagnostics Reports Fourth Quarter And Full Year 2018 Financial Results; Provides Guidance For Full Year 2019

02/11/19

Quest Diagnostics Completes Acquisition of Laboratory Services Business of Boyce & Bynum Pathology Laboratories

01/22/19

Quest Diagnostics Named One of 2019 "World's Most Admired Companies" by Fortune Magazine for Fourth Consecutive Year

### Upcoming Events


Date	Title
03/12/19 10:15 a.m. ET	Barclays Global Healthcare Conference

### Recent SEC Filings

Filing Date	Form	Description
02/14/19	SC 13G	A statement of beneficial ownership of common stock by certain persons
02/14/19	8-K	Report of unscheduled material events or corporate event
02/12/19	SC 13G/AA	An amendment to the SC 13G filing
02/06/19	SC 13G/AA	An amendment to the SC 13G filing

## Analyst Estimates / Ratings

Mean Recommendation: 2.5



Unable to fulfill request.

### Board of Directors

**Stephen H. Rusckowski**

Chairman, President and Chief Executive Officer

**Dan C. Stanzione, Ph.D.**

Lead Independent Director

**Jenne K. Britell, Ph.D.**

Director

**Vicky B. Gregg**

Director

**Jeffrey M. Leiden, M.D., Ph.D.**

Director

**Timothy L. Main**

Director

**Gary M. Pfeiffer**

Director

**Timothy M. Ring**

Director

**Helen I. Torley, M.B. Ch. B., M.R.C.P.**

Director

**Gail R. Wilensky, Ph.D.**

Director

### Management Team

**Stephen H. Rusckowski**

Chairman, President and Chief Executive Officer

**Everett Cunningham**

Senior Vice President, Commercial

**James E. Davis**

Executive Vice President, General Diagnostics

**Catherine T. Doherty**

Senior Vice President and Group Executive – Clinical Franchise Solutions & Marketing

**Carrie Eglinton Manner**

Senior Vice President, Advanced Diagnostics

**Mark J. Guinan**

Executive Vice President and Chief Financial Officer

**Cecilia McKenney**

Senior Vice President, Chief Human Resources Officer

**Michael E. Prevoznik**

Senior Vice President and General Counsel

**Gary D. Samuels**

Vice President, Corporate Communications

**Tim Sharpe**

Vice President, Compliance

**Dermot Shorten**

Senior Vice President, Strategy, M&A and Ventures

**Jay G. Wohlgemuth M.D.**

Senior Vice President, R&D, Medical and Chief Medical Officer

### Ownership Summary

#### Top Holders

	Shares Held	% O/S	Share Change	Filing Date
The Vanguard Group, Inc.	14,884,027	10.9	383,737	12/31/18
BlackRock Institutional Trust Company, N.A.	8,053,563	5.9	535,516	12/31/18
Macquarie Investment Management	6,699,892	4.9	306,807	09/30/18
State Street Global Advisors (US)	6,326,971	4.7	8,126	12/31/18
American Century Investment Management, Inc.	5,237,528	3.9	1,128,002	12/31/18
Fiduciary Management, Inc.	4,214,683	3.1	120,057	12/31/18
Victory Capital Management Inc.	2,811,037	2.1	135,312	12/31/18
Two Sigma Investments, LP	2,369,676	1.7	964,808	12/31/18
Geode Capital Management, L.L.C.	2,145,984	1.6	225,712	12/31/18
Marshall Wace LLP	2,051,729	1.5	-1,566,696	12/31/18